



WOAH Collaborative Centre Reports Activities 2024

This report has been submitted: 2 février 2025 19:04

CENTRE INFORMATION

*Title of WOAHCollaborating Centre	African Union-Panafrican Veterinary Vaccine Center (AU PANVAC)
*Address of WOAHCollaborating Centre	PO BOX 1746, DEBRE ZEIT ETHIOPIA
*Tel:	+251 11 433 8001
*E-mail address:	aupanvac@africa-union.org
Website:	www.aupanvac.org
*Name Director of Institute (Responsible Official):	Dr Charles Bodjo
*Name (including Title and Position) of Head of the Collaborating Centre (WOAH Contact Point):	Name : Dr Charles Bodjo Position : Ag Director Institution : AU PANVAC Telephone: +251 11 433 8001 Email: bodjoc@africa-union.org
*Name of the writer:	Mrs CISSE Rahamatou MOUSTAPHA BOUKARY /Ms Ethel Chitsungo

TOR 1 AND 2: SERVICES PROVIDED

1. Activities as a centre of research, expertise, standardisation and dissemination of techniques within the remit of the mandate given by WOAHC

Category	Title of activity	Scope
		AU-PANVAC received a total of 405

--

Vaccines (true)	Vaccine Quality control	batches of vaccines and other biologicals for quality control testing. This included 337 vaccine batches, 35 diluents, 24 vaccine seeds, 3 cell lines, 3 kits, 2 sera, and 1 GMEM. AU-PANVAC surpassed its 2024 plan by 1.25% (received 405 batches, planned for 400). This is a significant improvement compared to 2023, where 91% (364 out of 400) of the plan was achieved. In 2024, LSD vaccine had the highest proportion among tested vaccines at 21.7% (73 out of 337 batches), followed by PPR (14.2%, 48 batches), ND (7.4%, 25 batches), and CBPP (7.1%, 24 batches).
-----------------	-------------------------	--

TOR 3: HARMONISATION OF STANDARDS

2. Proposal or development of any procedure that will facilitate harmonisation of international regulations applicable to the main focus area for which you were designated

Proposal title	Scope/Content	Applicable Area
Criteria for Assessment of PPR Thermotolerant Vaccine	PPR vaccine thermotolerant vaccine quality control	Laboratory Expertise Veterinary Products

3. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHP?

No

4. Did your Collaborating Centre maintain a network with other WOAHP Collaborating Centres (CC), Reference Laboratories (RL), or organisations designated for the same specialty, to coordinate scientific and technical studies?

Yes

Name of WOAHP CC/RL/other organisation(s)	Location	Region of networking Centre	Purpose
Pirbright Institute	United kingdom	Europa	FMD vaccine VNT testing
CIRAD	France	Europa	mccpp vaccine production

--

Sandia Laboratories	USA	América	Biorisk management capacity building
Bio-Angle Vacs (BAV)	Malaysia	Asia y el Pacífico	Evaluation of the STVAC7 Intranasal Spray vaccine for protection against <i>M. haemolytica</i>
Klybeck Life Sciences (KLS)	Saudi Arabia	Oriente Medio	Collaboration in vaccine quality control
MEVAC	Egypt	África	Collaboration in vaccine quality control
Animal Production and Health Laboratory of the Joint FAO/IAEA Centre	Austria	Europa	Coordination on Novel Test Approaches to Determine Efficacy and Potency of Irradiated and Other Vaccines Sequencing of vaccine seeds for genetic stability evaluation

TOR 4 AND 5: NETWORKING AND COLLABORATION

5. Did your Collaborating Centre maintain a network with other WOAHC Collaborating Centres, Reference laboratories, or organisations in other disciplines, to coordinate scientific and technical studies?

Yes

Name of WOAHC CC/RL/other organisation(s)	Location	Region of networking Centre	Purpose
IZS Teramo	Italy	Europe	Vaccine seed sequencing

--

IAEA	Austria	Europe	Vaccine seed sequencing
Sciencano	Belgium	Europe	Vaccine seed sequencing

TOR 6: EXPERT CONSULTANTS

6. Did your Collaborating Centre place expert consultants at the disposal of WOA?H?

Yes

Name of expert	Kind of consultancy	Subject
Dr Charles Bodjo Ms Ethel Chitsungo Mr Hassen Belay	Electronic Expert Group on Autogenous Vaccines	WOAH reflection paper on Autogenous vaccines
Dr Charles Bodjo	Electronic Expert Group of Substandard & Falsified Veterinary Products (SFVP)	Guidance for Post-Marketing Surveillance (PMS) of Veterinary Products

TOR 7: SCIENTIFIC AND TECHNICAL TRAINING

7. Did your Collaborating Centre provide advice/services to requests from Members in your main focus area?

Yes

Support provided to South Africa regulatory authority on technical information on the Rift Valley Fever vaccine seed.

Technical support to NVI for quality control of Rinderpest vaccine

Support quality of veterinary vaccines by harmonisation of standard operating procedures used to the detection of BVD virus in vaccines

8. Did your Collaborating Centre provide scientific and technical training, within the remit of the mandate given by WOA?H, to personnel from WOA?H Members?

Yes

a) Technical visit : 11

b) Seminars : 0

c) Hands-on training courses: 6

--

d) Internships (>1 month) : 8

Type of technical training provided (a, b, c or d)	Content	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
A	Vaccine production, quality control and quality management	Nigeria	11
C	Production and quality control of Haemorrhagic septicaemia and Anthrax vaccines	Zambia	4
C	Production and quality control of the PPR vaccine	Mongolia	2
D	Molecular diagnostic technics	Chad	4
D	Internship and master's degree	PAU, Nigeria	3
D	Internship project and master's degree project	AAU, Ethiopia	1

TOR 8: SCIENTIFIC MEETINGS

9. Did your Collaborating Centre organise or participate in the organisation of scientific meetings related to your main focus area on behalf of WOA?H?

Yes

National/International	Title of event	Co-organiser	Date	Location	No. Participants
Internationally	Second Meeting of the Standing Group of Experts (SGE) on Contagious Bovine Pleuro-Pneumonia (CBPP) of the GF-TADs for Africa Lusaka,	AU-PANVAC, AU-IBAR, FAO and WOA?H	2024-07-23	LUSAKA, ZAMBIA	20

	Zambia 23 – 25 July 2024				
Internationally	Virtual Meeting to discuss the Collaboration to improve PPR Vaccine production in Africa- Public and private sector	AU-PANVAC and AU-IBAR	2024-07-31	Online, meeting	15

TOR 9: DATA AND INFORMATION DISSEMINATION

10. Publication and dissemination of any information within the remit of the mandate given by WOAHA that may be useful to Members of WOAHA

a) Articles published in peer-reviewed journals:

2

1. *Amadou Diallo et al. An Evaluation of the Thermotolerance of Various Formulations of Freeze-Dried and Reconstituted Peste des Petits Ruminant Vaccines. Vet. Sci. 2024, 11(11), 525; <https://doi.org/10.3390/vetsci11110525>*

2. *Boubacar Barry et al. Partial Sequence Analysis of Commercial Peste des Petits Ruminants Vaccines Produced in Africa. Vet. Sci. 2024, 11(10), 500; <https://doi.org/10.3390/vetsci11100500>*

b) International conferences:

14

1. *The 1st Inter-REC PPR Coordination Meeting, Casablanca, Morocco, April 2024*

2. *Animal Health Experts Meeting, April 2024, Naivasha, Kenya*

3. *16th Pan African CVOs and WOAHA Delegates Meeting & Collaborative Partnership AU-IBAR and AU-PANVAC Discussions, May 2024, Nairobi, Kenya*

4. *91st WOAHA General Session Face-to-face, May 2024, Paris, France*

5. *Second Research Coordination Meeting on Novel Test Approaches to Determine Efficacy and Potency of Irradiated and Other Vaccines at the IAEA's Headquarters in Vienna, Austria, from 10 to 14 June 2024.*

6. *the Second Meeting of the Standing Group of Experts on Contagious Bovine Pleuropneumonia (SGE CBPP) for Africa, July 2024, Lusaka, Zambia*

7. *Training Workshop: FMD epidemiology, diagnostics and surveillance for strengthening FMD control in Southern Africa, August 2024, Maseru, Lesotho*

8. *Joint Meeting of the Foot and Mouth Disease (FMD) Regional Roadmap for Eastern and Southern Africa, September 2024, Dar es Salaam, Tanzania*

9. *Workshop on the Development of Irradiated Vaccines. September 2024, Tunis, Tunisia*



10. *Global Conference on Animal Health Innovation, Reference Centres and Vaccines, FAO, September 2024, Rome, Italy*

11. *4th Meeting of the sub-committee on sanitary and phytosanitary measures, Lusaka (Zambia), 9-13 Nov. 2024*

12. *WOAH PMS meeting, October 2024, Online*

13. *Aquatic Animal vaccine meeting, October 2024, Online*

14. *Electronic Expert Group (EEG) meeting on Autogenous Vaccine. 3 online meetings*

c) National conferences:

d) Other (Provide website address or link to appropriate information):

1

<https://doi.org/10.5281/zenodo.13774656>

11. What have you done in the past year to advance your area of focus, e.g. updated technology?

Define Criteria for Assessment of PPR Thermotolerant Vaccine: 2 criteria

(1) PPR vaccine titer (dose) should be above 2.5 log₁₀ TCID₅₀/ml after post exposure at 40°C/ 5 Days

(2.1) Titer loss after post exposure at 40°C/ 5 Days ≤ 1 log₁₀

OR

(2.2) Titer loss after post exposure at 40°C between Day3 and Day5 should be ≤ 0.4 log₁₀ to guarantee vaccine potency if cold chain is not maintained

Transportation of such vaccine (W/O maintaining the cold chain) can be done up to maximum of 21 days to ensure vaccine potency

12. Additional comments regarding your report:

N/A